Status:
ENROLLING_BY_INVITATION
KIDNEY-PAGER: Analysis of Circulating Tumor DNA as a Biomarker in Renal Cancer - an Observational Trial
Lead Sponsor:
University of Aarhus
Conditions:
Renal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The overall aim of this observational study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for renal cell carcinoma (RCC) can be app...
Detailed Description
OBJECTIVES The overall objective of the study is to confirm that circulating tumor DNA (ctDNA) detected in plasma and or urine after intended curative treatment for RCC can be applied in clinical pra...
Eligibility Criteria
Inclusion
- Patients diagnosed with a locoregional cancer in the kidney, and with a tumour available for surgical excision, and sufficient performance status for surgery.
- Patients with M1 disease, but no evidence of disease after surgery and local treatment of the metastases.
- Core needle biopsy-proven renal cell carcinoma - all histologic subtypes acceptable, clinical tumour stage I-IV
- Patients 18 years or older
- Patients able to understand and sign written informed consent
- Scheduled for curative intent resectional surgery (partial or radical nephrectomy)
Exclusion
- Patients with local disease who are not being offered a nephrectomy.
- Patients who are unlikely to comply with the protocol (e.g. uncooperative attitude), inability to return for subsequent visits and/or otherwise considered by the Investigator to be unlikely to complete the study
Key Trial Info
Start Date :
June 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2033
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT06145139
Start Date
June 1 2023
End Date
June 1 2033
Last Update
November 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology Department Aarhus University Hospital
Aarhus N, Denmark